Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline.
Shanler
Stuart D
SD
School of Medicine, University of New Mexico, Albuquerque, USA. sdsmd@aspectpharma.com
Ondo
Andrew L
AL
D058646:Adrenergic alpha-1 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000368:Aged; D004890:Erythema / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D005260:Female; D005483:Flushing / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010109:Oxymetazoline / Q000627:therapeutic use*; D017060:Patient Satisfaction; D012393:Rosacea / Q000150:complications*; D013684:Telangiectasis / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome
D058646:Adrenergic alpha-1 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D010109:Oxymetazoline